Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 2001 May;45(5):1578–1580. doi: 10.1128/AAC.45.5.1578-1580.2001

Macrolide Resistance in Streptococcus pneumoniae in Hong Kong

Margaret Ip 1,*, Donald J Lyon 1, Raymond W H Yung 2, Colin Chan 1, Augustine F B Cheng 1
PMCID: PMC90511  PMID: 11302833

Abstract

Erythromycin resistance rates among penicillin-susceptible Streptococcus pneumoniae were 38 and 92% among penicillin-intermediate and -resistant S. pneumoniae isolates from Hong Kong, respectively, and 27% (43 of 158) of the isolates showed the MLSB phenotype, and the majority carried the ermB gene; 73% (115 of 158) displayed the M phenotype, and all possessed the mef gene. The MLSB phenotype was predominant in penicillin-susceptible, macrolide-resistant isolates and in penicillin-nonsusceptible isolates of serotype 6B, whilst the M phenotype was predominant in penicillin-intermediate or -resistant isolates belonging to serotype 23F or 19F. Extensive spread of clones of drug-resistant pneumococci has led to the widespread presence of macrolide resistance in S. pneumoniae in Hong Kong.


Macrolide resistance among Streptococcus pneumoniae has increased in many countries, such as the United States (2, 3) and United Kingdom (4). Two principal mechanisms of macrolide resistance have been described (10); target modification is mediated by an rRNA erythromycin resistance methylase and coded by the ermB (ermAM) gene. These organisms express the MLSB phenotype and show broad cross-resistance to macrolides, lincosamides, and streptogramin B antibiotics. The M phenotype involves an active efflux pump, which removes only 14-membered and 15-membered macrolides from the bacterial cell (14). The determinant was identified to be the mef (mefE) gene (15). Isolates showing the M phenotype are susceptible to clindamycin and streptogramin B. In 1999, two further mechanisms were described, one mediated by alterations in the L4 ribosomal protein, and another due to mutation in the 23S rRNA (15a). The incidence of erythromycin resistance in pneumococci at the Prince of Wales Hospital, Hong Kong, has risen from 22% in 1993 to 42% in 1997 (6). The likely explanation is the dissemination of a few clones of multidrug-resistant S. pneumoniae in the Hong Kong population as previously described (5). The objective of the present study was to investigate the prevalence and distribution of the macrolide resistance determinants in isolates of S. pneumoniae in Hong Kong. In addition, the relationships between these determinants, penicillin susceptibility, and their serotypes were also determined.

A total of 197 strains of S. pneumoniae isolated at the Prince of Wales Hospital and Pamela Youde Nethersole Eastern Hospital, Hong Kong, from 1994 to 1998 were studied. Approximately 25% were invasive isolates from blood and cerebrospinal fluid, and the remainder were from sputum which had reduced penicillin susceptibility by the 1-μg oxacillin disk method. The two hospitals are located in the northern and southern parts of Hong Kong, and the isolates were thus deemed to be representative of strains from patients with pneumococcal infections requiring hospital admissions in Hong Kong. The penicillin-intermediate or -resistant isolates had previously been well characterized by molecular typing using pbp gene profiles and pulsed-field gel electrophoresis (PFGE) (5).

MICs of penicillin, erythromycin, clarithromycin, and clindamycin were determined by the agar dilution method (8). Inocula of 104 CFU/spot were incubated at 35°C for 18 h on Mueller-Hinton agar supplemented with 5% defibrinated horse blood. S. pneumoniae ATCC 6315 and 49619 were included as controls. Inducible resistance to clindamycin was detected by the method previously described (11). Conserved primer sets were chosen to amplify a 640-bp fragment of the erm methylase genes as follows: ermA, 5′-TCTAAAAAGCATGTAAAAGAA-3′ and 5′-CTTCGATAGTTTATTAATATTAGT-3′; ermB, 5′-GAAAAGGGTACTCAACCAAATA-3′ and 5′-AGTAACGGTACTTAAATTGTTTAC-3′; and ermC, 5′-TCAAAACATAATATAGATAAA-3′ and 5′-GCTAATATTGTTTAAATCGTCAAT-3′. A 1.2-kb fragment of the mef gene in S. pneumoniae was amplified using primer pair 5′-GAAAAATACAACAATTGGAAAC-3′ and 5′-AATCTAATTTTCTAACCTCA-3′. PCRs were performed on the OmniGene DNA thermal cycler (Hybaid) using an initial denaturation at 94°C for 5 min followed by 35 cycles of amplification at 94°C for 30 s, 50°C for 30 s, and 72°C for 90 s. A final elongation step was performed at 72°C for a further 7 min. All the strains were serotyped by the chessboard agglutination or the quellung reaction method using Pneumotest antisera (Statens Seruminstitut, Copenhagen, Denmark).

A total of 80% (158 of 197) of the S. pneumoniae strains were resistant to erythromycin with a MIC of ≥1.0 μg/ml, 27% (43 of 158) showed an MLSB phenotype with erythromycin and clindamycin 50% and 90% MICs (MIC50 and MIC90) of >64 μg/ml; 73% (115 of 158) showed resistance to erythromycin alone, with MIC50 and MIC90 of 8.0 μg/ml. The MICs of the antibiotics tested for these two groups are shown in Table 1. Of the isolates expressing the MLSB phenotype, only the ermB gene was detected in 93% of the isolates by PCR. Three isolates were repeatedly negative on testing for ermA, -B, or -C, and hence perhaps other mechanisms of macrolide resistance exist. All the isolates expressing the M phenotype were positive for the mef gene by PCR. Table 2 shows the serotypes of S. pneumoniae in relation to penicillin and macrolide susceptibility. Among the 42 penicillin-susceptible isolates, 16 (38%) isolates were resistant to erythromycin with a MIC of ≥1.0 μg/ml, and 62.5% of the penicillin-susceptible, macrolide-resistant isolates showed the MLSB phenotype. However, of the 155 penicillin-intermediate or -resistant isolates examined, 142 (92%) isolates were resistant to erythromycin, 107 of 142 (75%) of these belonged to the M phenotype, whilst the remainder (35 of 142, 25%) belonged to the MLSB phenotype, with a MLSB/M phenotype ratio of 1:3. The MLSB phenotype was mainly associated with serotype 6B (P > 0.001, chi square test), whilst the M phenotype was predominant in isolates expressing serotype 23F or 19F (P > 0.001, chi square test).

TABLE 1.

MICs of 197 Hong Kong S. pneumoniae isolates for four antibiotics by macrolide and lincosamide susceptibility phenotypes

Macrolide phenotypea (no. of strains) MIC range (μg/ml) MIC50 (μg/ml) MIC90 (μg/ml)
Penicillin
 MLSB (43) <0.03–2.0 1.0 2.0
 M (115) <0.03–4.0 1.0 2.0
 S (39) <0.03–2.0 0.03 1.0
Erythromycin
 MLSB (43) 8.0–>64.0 >64.0 >64.0
 M (115) 1.0–64.0 8.0 8.0
 S (39) 0.12–0.25 0.25 0.25
Clarithromycin
 MLSB (43) 8.0–>64.0 >64.0 >64.0
 M (115) 1.0–64.0 8.0 8.0
 S (39) 0.12–0.25 0.25 0.25
Clindamycin
 MLSB (43) 1.0–>64.0 >64.0 >64.0
 M (115) 0.12–0.5 0.25 0.25
 S (39) 0.12–0.25 0.25 0.25
a

MLSB, macrolide and lincosamide resistance phenotype; M, erythromycin-resistant, clindamycin-susceptible phenotype; S, erythromycin- and clindamycin-susceptible isolates. 

TABLE 2.

Serotypes of S. pneumoniae in relation to penicillin and macrolide susceptibilitya (197 isolates)

Serotype and macrolide phenotype No. of isolates with the following penicillin susceptibility:
S I or R
23F
 S 3 9
 RMLSB 3 5
 RM 2 64
19F
 S 1 0
 RMLSB 0 3
 RM 0 39
6B
 S 1 3
 RMLSB 0 23
 RM 2 3
14
 S 0 0
 RMLSB 3 2
 RM 2 3
Other
 S 21 1
 RMLSB 4 0
 RM 0 0
Total 42 155
a

S, sensitive; I, intermediate; R, resistant; MLSB, macrolide and lincosamide resistance phenotype; M, erythromycin-resistant, clindamycin-susceptible phenotype. 

The study indicated a high percentage of erythromycin resistance among clinical isolates of S. pneumoniae in Hong Kong, with 38% in penicillin-susceptible pneumococci and 92% of penicillin-intermediate or -resistant isolates. Our previous study (5) showed that these strains belonging to 19F and 23F had identical pbp profiles and PFGE fingerprints and belong to clones indistinguishable from that belonging to the Spanish 23F clone. Similarly, isolates belonging to serotype 6B had unique pbp profiles and identical PFGE fingerprints to that of the Spanish 6B clone (5). The data further support the hypothesis that the dissemination of particular clones of S. pneumoniae of reduced penicillin susceptibility has been responsible for the spread of macrolide resistance determinants in Hong Kong. In Canada and the United States, the M phenotype was prevalent in 55.8 and 71%, respectively, of the macrolide-resistant pneumococci (3, 7). In contrast, the MLSB resistance mechanism predominates in European countries, and the mef gene was only found in 1, 5.8, and 9% among resistant pneumococci in France (P. Angot, M. Vergnaud, and R. Leclerq, Program Abstr. 39th Intersci. Conf. Antimicrob. Agents. Chemother. abstr. 1221, 1999), Italy (9), and Belgium (1) respectively. Macrolide resistance has been reported to be high among pneumococci in Asian countries (13), but the distribution of these macrolide resistance determinants is not known. As in Hong Kong, penicillin- and multidrug-resistant S. pneumoniae clones belonging to serotypes 19 and 23 disseminated widely in the last decade in Taiwan (12), Korea (17), and Japan (18), and it is likely that the mef genes are prevalent among the penicillin-resistant pneumococci in these countries too.

The 14- and 15-membered macrolides have poor activity against Hong Kong clinical isolates of S. pneumoniae, particularly against penicillin-intermediate or -resistant strains. This study supported the widespread dissemination of the macrolide resistance determinants, particularly the mef gene, which occurred with the spread of penicillin-nonsusceptible pneumococcal clones in Hong Kong.

Acknowledgments

The work described in this paper was fully supported by grants from the Research Grants Council of the Hong Kong Special Administrative Region (Project Nos. CUHK 4215/97M and 4331/99M).

REFERENCES

  • 1.Descheemaeker P, Chapelle S, Lammens C, Hauchecorne M, Wijdooghe M, Vandamme P, Ieven M, Goossens H. Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates. J Antimicrob Chemother. 2000;45:167–173. doi: 10.1093/jac/45.2.167. [DOI] [PubMed] [Google Scholar]
  • 2.Doern G V, Pfaller M A, Kugler K, Freeman J, Jones R N. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America; 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis. 1998;27:764–770. doi: 10.1086/514953. [DOI] [PubMed] [Google Scholar]
  • 3.Doern G V, Brueggemann A B, Huynh H, Wingert E, Rhomberg P. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997–98. Emerg Infect Dis. 1999;5:757–765. doi: 10.3201/eid0506.990603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Hall L M C, Whiley R A, Duke B, George R C, Efstratiou A. Genetic relatedness within and between serotypes of Streptococcus pneumoniae from the United Kingdom: analysis of multilocus enzyme electrophoresis, pulsed-field gel electrophoresis, and antimicrobial resistance patterns. J Clin Microbiol. 1996;34:853–859. doi: 10.1128/jcm.34.4.853-859.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Ip M, Lyon D J, Yung R W H, Chan C, Cheng A F B. Evidence of clonal dissemination of multidrug-resistant Streptococcus pneumoniae in Hong Kong. J Clin Microbiol. 1999;37:2834–2839. doi: 10.1128/jcm.37.9.2834-2839.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Ip M, Lyon D J, Cheng A F B. Patterns of antibiotic resistance, serotype distribution, and patient demographics of Streptococcus pneumoniae in Hong Kong. Chemotherapy. 2001;47:110–116. doi: 10.1159/000048509. [DOI] [PubMed] [Google Scholar]
  • 7.Johnston N J, De A J, Kellner J D, Low D E. Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1998;42:2425–2426. doi: 10.1128/aac.42.9.2425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, 8th informational supplement, M100–S8. 5th ed. Villanova, Pa: National Committee for Clinical Laboratory Standards; 1998. [Google Scholar]
  • 9.Oster P, Zanchi A, Cresti S, Lattanzi M, Montagnani F, Cellesi C, Rossolini G M. Patterns of macrolide resistance determinants among community-acquired Streptococcus pneumoniae isolates over a 5-year period of decreased macrolide susceptibility rates. Antimicrob Agents Chemother. 1999;43:2510–2512. doi: 10.1128/aac.43.10.2510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Roberts M C, Sutcliffe J, Courvalin P, Jensen L B, Rood J, Seppala H. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother. 1999;43:2823–2830. doi: 10.1128/aac.43.12.2823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Seppala H, Nissinen A, Yu Q, Huovinen P. Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland. J Antimicrob Chemother. 1993;32:885–891. doi: 10.1093/jac/32.6.885. [DOI] [PubMed] [Google Scholar]
  • 12.Shi Z Y, Enright M C, Wilkinson P, Griffiths D, Spratt B G. Identification of three major clones of multiply antibiotic-resistant Streptococcus pneumoniae in Taiwanese hospitals by multilocus sequence typing. J Clin Microbiol. 1998;36:3514–3519. doi: 10.1128/jcm.36.12.3514-3519.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Song J H, Lee N Y, Ichiyama S, Yoshida R, Hirakata Y, Fu W, Chongthaleong A, Aswapokee N, Chiu C H, Lalitha M K, Thomas K, Perera J, Yee T T, Jamai F, Warsa U C, Vinh B X, Jacobs M R, Appelbaum P C, Pai C H the ANSORP Study Group. Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study. Clin Infect Dis. 1999;28:1206–1211. doi: 10.1086/514783. [DOI] [PubMed] [Google Scholar]
  • 14.Sutcliff J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother. 1996;40:1817–1824. doi: 10.1128/aac.40.8.1817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Tait-Kamradt A, Clancy J, Cronan M, Dib-Haji F, Wondrack L, Yuan W, Sutcliffe J. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1997;41:2251–2255. doi: 10.1128/aac.41.10.2251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15a.Tait-Kamradt A, Davies T, Cronan M, Jacobs M R, Appelbaum P C, Sutcliffe J. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother. 2000;44:2118–2125. doi: 10.1128/aac.44.8.2118-2125.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Tarasi A, Chong Y, Lee K, Tomasz A. Spread of the serotype 23F multidrug-resistant Streptococcus pneumoniae clone to South Korea. Microb Drug Resist. 1997;3:105–109. doi: 10.1089/mdr.1997.3.105. [DOI] [PubMed] [Google Scholar]
  • 17.Yoshida R, Hirakata Y, Kaku M, Takemura H, Tanaka H, Tomono K, Koga H, Kohno S, Kamihira S. Genetic relationship of penicillin resistant Streptococcus pneumoniae serotype 19B strains in Japan. Epidemiol Infect. 1997;118:105–110. doi: 10.1017/s0950268896007273. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES